Antares Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Antares Pharma generated cash of $36,619,000, which is more than the previous year. Cash used in financing activities reached the amount of -$19,990,000 last year. Net change in cash is therefore $12,776,000.
Cash Flow
| 2012 | -10.47M | -21.66M | 64.87M |
|---|---|---|---|
| 2013 | -14.96M | -293.12K | 2.22M |
| 2014 | -26.33M | 18.34M | 2.95M |
| 2015 | -28.19M | -15.72M | 42.79M |
| 2016 | -15.19M | 9.99M | 17.46K |
| 2017 | -23.09M | -4.33M | 26.27M |
| 2018 | -17.32M | 11.60M | 7.04M |
| 2019 | -10.61M | -19.99M | 25.91M |
| 2020 | 21.32M | 8.16M | 447K |
| 2021 | 36.61M | -3.85M | -19.99M |
ATRS Cash Flow Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 53.13M | 23.20M | 27.89M | 26.56M | 27.71M | 32.89M | 34.02M | 39.06M | 52.09M | 19.35M |
Operating activities | ||||||||||
Net income | 46.28M | 56.20M | -2.02M | -6.51M | -16.74M | -24.33M | -20.65M | -35.15M | -20.50M | -11.42M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 3.90M | 2.62M | 2.55M | 2.72M | 2.10M | 1.86M | 1.56M | 1.22M | 558.28K | 231.02K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.43M | 2.02M |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.43M | 2.02M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -14.47M | -7.12M | -16.09M | -7.09M | -2.79M | -1.13M | -4.42M | -2.47M | 1.19M | 310.81K |
Inventories | 152K | -2.72M | -4.97M | -2.66M | -4.30M | -350.94K | -564.47K | -2.94M | -5.46M | -118.36K |
Accounts payable | 2.18M | 2.59M | 926K | 5.16M | -1.52M | 2.85M | -3.49M | 2.68M | 2.52M | 724.80K |
Cash generated by operating activities | 36.61M | 21.32M | -10.61M | -17.32M | -23.09M | -15.19M | -28.19M | -26.33M | -14.96M | -10.47M |
Investing activities | ||||||||||
Purchases Of Investments | -1.24M | 0 | -22.64M | 0 | -9.96M | 0 | -15.03M | 0 | -21.12M | -30.16M |
Investments In Property Plant And Equipment | -6.61M | -14.61M | -2.35M | -894K | -1.26M | -5.00M | -6.68M | -5.65M | -3.16M | -3.25M |
Acquisitions Net | 0 | 0 | 0 | 0 | 101K | 0 | 1.04M | 0 | 420.33K | 0 |
Cash generated by investing activities | -3.85M | 8.16M | -19.99M | 11.60M | -4.33M | 9.99M | -15.72M | 18.34M | -293.12K | -21.66M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 7.78M | 7.11M | 0 | 0 | 42.85M | 0 | 0 | 53.32M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -40M | -1.36M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -19.99M | 447K | 25.91M | 7.04M | 26.27M | 17.46K | 42.79M | 2.95M | 2.22M | 64.87M |
Net Change In Cash | 12.77M | 29.93M | -4.69M | 1.33M | -1.15M | -5.18M | -1.13M | -5.03M | -13.02M | 32.73M |
Cash at end of period | 65.91M | 53.13M | 23.20M | 27.89M | 26.56M | 27.71M | 32.89M | 34.02M | 39.06M | 52.09M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |